Table 2 Treatment-related characteristics, overall and by sex
Treatment-related Characteristics | Sample n = 318 (%) | Male n = 80 (%) | Female n = 238 (%) | Chi2 P Value |
|---|---|---|---|---|
Duration of ART (years): Median (IQR) | 4 (2–7) | 3 (2–6) | 4 (2–7) | 0.09c |
 0.5–2.5 | 89 (27) | 26 (33) | 63 (26) |  |
 2.6–4.0 | 76 (24) | 25 (31) | 51 (22) | 0.09 |
 4.1–6.0 | 59 (19) | 12 (15) | 47 (20) |  |
  > 6.0 | 94 (30) | 17 (21) | 77 (32) |  |
Most recent Viral load (copies/ml) | ||||
 Detectable | 60 (19) | 18 (22) | 42 (18) | 0.34 |
 Not detectable (LDL/< 40) | 258 (81) | 62 (78) | 196 (82) |  |
Time since last VL: Median (IQR) (months) | 7 (4–11) | 5 (3–10) | 7 (4–11) | 0.21c |
Most recent CD4 count (n = 299; inc. 76 males) | ||||
Binary Indicator (cells/mm3): | ||||
Low (≤350) | 92 (31) | 35 (46) | 57 (25) | < 0.001 |
High (> 350) | 207 (69) | 41 (54) | 166 (75) |  |
Categorised CD4 | ||||
Low: 0–299 | 73 (24) | 28 (37) | 45 (20) | < 0.001 |
300–449 | 58 (20) | 17 (22) | 41 (19) |  |
450–599 | 79 (26) | 21 (28) | 58 (26) |  |
High: ≥600 | 89 (30) | 10 (13) | 79 (35) |  |
Time since last CD4 measurement: Median (IQR) (months) (n = 299; inc. 76 males) | 8 (4–12) | 6 (3–11) | 8 (4–12) | 0.31c |